Association between cardiotoxicity and anticancer drugs
Cancer and heart disease are two of the major causes of death in the world. In the last few decades, there is a rapid development in cancer therapies and early detection strategies, hence the death rates caused by cancer have decreased.
Although survival rates have improved, it is observed that cardiovascular disease has become the second leading cause of long-term morbidity and fatality among cancer survivors. Therefore, the risk of cardiotoxicity is one of the major limitations in oncology drug development. Cardiotoxicity can occur during any stage of the cancer and it includes, but is not limited to, subclinical myocardial toxicity, ischemia, hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction, coronary artery disease and heart failure.
The aim of my research is to investigate the association between cardiotoxicity and anticancer drugs for lung cancer by using clinical trials data and real-world data, and thus develop potential mitigation related to cardiotoxicity in cancer patients.
Ho Yi Stefanie Chan
Clinical, Pharmaceutical and Biological Science
School of Life and Medical Sciences
Association between cardiotoxicity and anticancer drugs
Cancer and heart disease are two of the major causes of death in the world. In the last few decades, there is a rapid development in cancer therapies and early detection strategies, hence the death rates caused by cancer have decreased.
Although survival rates have improved, it is observed that cardiovascular disease has become the second leading cause of long-term morbidity and fatality among cancer survivors. Therefore, the risk of cardiotoxicity is one of the major limitations in oncology drug development. Cardiotoxicity can occur during any stage of the cancer and it includes, but is not limited to, subclinical myocardial toxicity, ischemia, hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction, coronary artery disease and heart failure.
The aim of my research is to investigate the association between cardiotoxicity and anticancer drugs for lung cancer by using clinical trials data and real-world data, and thus develop potential mitigation related to cardiotoxicity in cancer patients.
Ho Yi Stefanie Chan
Clinical, Pharmaceutical and Biological Science
School of Life and Medical Sciences